These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 37827842)
1. First-in-Humans PET Imaging of Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842 [TBL] [Abstract][Full Text] [Related]
2. Activity and resistance to KRAS Ye W; Lu X; Qiao Y; Ou WB Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697 [TBL] [Abstract][Full Text] [Related]
3. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination. Rosell R; Jantus-Lewintre E; Cao P; Cai X; Xing B; Ito M; Gomez-Vazquez JL; Marco-Jordán M; Calabuig-Fariñas S; Cardona AF; Codony-Servat J; Gonzalez J; València-Clua K; Aguilar A; Pedraz-Valdunciel C; Dantes Z; Jain A; Chandan S; Molina-Vila MA; Arrieta O; Ferrero M; Camps C; González-Cao M Cell Commun Signal; 2024 Jun; 22(1):324. PubMed ID: 38867255 [TBL] [Abstract][Full Text] [Related]
5. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403 [TBL] [Abstract][Full Text] [Related]
6. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC). Parums DV Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327 [TBL] [Abstract][Full Text] [Related]
7. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation. Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531 [TBL] [Abstract][Full Text] [Related]
8. Correlation between Liu X; Wang SC; Ni M; Xie Q; Zhang YF; Lv WF; Geng GY Abdom Radiol (NY); 2022 Apr; 47(4):1255-1264. PubMed ID: 35138462 [TBL] [Abstract][Full Text] [Related]
9. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer. Lee A Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377 [TBL] [Abstract][Full Text] [Related]
10. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer. Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS Hoshiyama H Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617 [TBL] [Abstract][Full Text] [Related]
13. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. Lee SM; Bae SK; Jung SJ; Kim CK Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571 [TBL] [Abstract][Full Text] [Related]
14. Correlation between KRAS mutation and Cho A; Jo K; Hwang SH; Lee N; Jung M; Yun M; Hwang HS Abdom Radiol (NY); 2017 Jun; 42(6):1621-1626. PubMed ID: 28161825 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of F-18 FDG PET/CT for prediction of KRAS mutation in colorectal cancer patients: a systematic review and meta-analysis. Kim SJ; Pak K; Kim K Abdom Radiol (NY); 2019 May; 44(5):1703-1711. PubMed ID: 30603881 [TBL] [Abstract][Full Text] [Related]
17. Using tumor habitat-derived radiomic analysis during pretreatment Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905 [TBL] [Abstract][Full Text] [Related]
18. Relationship between KRAS mutations and dual time point Mao W; Zhou J; Zhang H; Qiu L; Tan H; Hu Y; Shi H Abdom Radiol (NY); 2019 Jun; 44(6):2059-2066. PubMed ID: 30143816 [TBL] [Abstract][Full Text] [Related]
19. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674 [TBL] [Abstract][Full Text] [Related]
20. Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients. Krikelis D; Skoura E; Kotoula V; Rondogianni P; Pianou N; Samartzis A; Xanthakis I; Fountzilas G; Datseris IE Anticancer Res; 2014 May; 34(5):2571-9. PubMed ID: 24778079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]